Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
or

Lexicon Pharmaceutcl (LXRX)

Lexicon Pharmaceutcl (LXRX)
0.4189 -0.0243 (-5.48%) 04/04/25 [NASDAQ]
0.3822 x 1,900 0.4000 x 800
Realtime by (Cboe BZX)
0.3822 x 1,900 0.4000 x 800
Realtime 0.3831 -0.0358 (-) 05:41 ET
Quote Overview for Fri, Apr 4th, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
0.4100
Day High
0.4620
Open 0.4114
Previous Close 0.4432 0.4432
Volume 10,961,200 10,961,200
Avg Vol 31,129,395 31,129,395
Stochastic %K 34.88% 34.88%
Weighted Alpha -76.35 -76.35
5-Day Change -0.1516 (-26.57%) -0.1516 (-26.57%)
52-Week Range 0.2800 - 2.4500 0.2800 - 2.4500
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 103,149
  • Shares Outstanding, K 246,237
  • Annual Sales, $ 31,080 K
  • Annual Income, $ -200,400 K
  • EBIT $ -197 M
  • EBITDA $ -195 M
  • 60-Month Beta 1.02
  • Price/Sales 3.51
  • Price/Cash Flow N/A
  • Price/Book 0.75
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.64
  • Most Recent Earnings $-0.09 on 03/06/25
  • Next Earnings Date 05/01/25 [--]
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Biomedical

Options Overview Details

View History
  • Implied Volatility 199.32% ( +13.75%)
  • Historical Volatility 312.58%
  • IV Percentile 69%
  • IV Rank 31.74%
  • IV High 558.03% on 02/24/25
  • IV Low 32.53% on 08/20/24
  • Put/Call Vol Ratio 0.77
  • Today's Volume 885
  • Volume Avg (30-Day) 1,661
  • Put/Call OI Ratio 0.09
  • Today's Open Interest 46,659
  • Open Int (30-Day) 40,582

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/25
See More
  • Average Estimate -0.10
  • Number of Estimates 3
  • High Estimate -0.08
  • Low Estimate -0.12
  • Prior Year -0.20
  • Growth Rate Est. (year over year) +50.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.3050 +37.34%
on 03/05/25
Period Open: 0.3248
0.7072 -40.77%
on 03/31/25
+0.0941 (+28.97%)
since 03/04/25
3-Month
0.2800 +49.61%
on 03/03/25
Period Open: 0.7886
1.0900 -61.57%
on 01/24/25
-0.3697 (-46.88%)
since 01/03/25
52-Week
0.2800 +49.61%
on 03/03/25
Period Open: 2.0600
2.4500 -82.90%
on 07/25/24
-1.6411 (-79.67%)
since 04/04/24

Most Recent Stories

More News
Lexicon Pharmaceuticals to Present at the 24th Annual Needham Virtual Healthcare Conference

LXRX : 0.4189 (-5.48%)
Lexicon Pharmaceuticals Announces Exclusive License Agreement with Novo Nordisk for LX9851

LXRX : 0.4189 (-5.48%)
Lexicon Pharmaceuticals to Present at the Leerink Partners Global Healthcare Conference 2025

LXRX : 0.4189 (-5.48%)
Lexicon: Q4 Earnings Snapshot

Lexicon: Q4 Earnings Snapshot

LXRX : 0.4189 (-5.48%)
Lexicon Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates

LXRX : 0.4189 (-5.48%)
Lexicon Pharmaceuticals to Report Fourth Quarter and Full Year 2024 Financial Results on March 6, 2025

LXRX : 0.4189 (-5.48%)
Lexicon Pharmaceuticals Announces Topline Results from Phase 2b PROGRESS Study Evaluating Pilavapadin (LX9211) in Adults with Diabetic Peripheral Neuropathic Pain

LXRX : 0.4189 (-5.48%)
Lexicon Pharmaceuticals to Announce Topline Results from Phase 2b PROGRESS Study Evaluating Pilavapadin (LX9211) in Adults with Diabetic Peripheral Neuropathic Pain

LXRX : 0.4189 (-5.48%)
Published Data in The Lancet Diabetes & Endocrinology Highlights Unique Efficacy Benefits of Sotagliflozin to Reduce Major Adverse Cardiovascular Events (MACE)

LXRX : 0.4189 (-5.48%)
Lexicon Announces Virtual Webcast on LX9211 for Diabetic Peripheral Neuropathic Pain

LXRX : 0.4189 (-5.48%)

Business Summary

Lexicon Genetics Incorporated is a leader in defining the functions of genes for drug discovery using large-scale knockout mouse technology. Lexicon has invented high-throughput gene trapping technology to discover thousands of genes and expand its OmniBank library of tens of thousands of mouse clones....

See More

Key Turning Points

3rd Resistance Point 0.5026
2nd Resistance Point 0.4823
1st Resistance Point 0.4506
Last Price 0.4189
1st Support Level 0.3986
2nd Support Level 0.3783
3rd Support Level 0.3466

See More

52-Week High 2.4500
Fibonacci 61.8% 1.6211
Fibonacci 50% 1.3650
Fibonacci 38.2% 1.1089
Last Price 0.4189
52-Week Low 0.2800

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
Trader's Cheat Sheet: Your Secret Weapon for Smarter Trades